Suppr超能文献

镰状细胞贫血患者白蛋白尿的进展:一项多中心、纵向研究。

Progression of albuminuria in patients with sickle cell anemia: a multicenter, longitudinal study.

机构信息

Division of Hematology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.

Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.

出版信息

Blood Adv. 2020 Apr 14;4(7):1501-1511. doi: 10.1182/bloodadvances.2019001378.

Abstract

Sickle cell nephropathy results in chronic kidney disease (CKD), which is associated with significant morbidity and mortality in sickle cell anemia (SCA). Albuminuria is an early manifestation of sickle nephropathy; however, little is known about progression of albuminuria or its correlation with glomerular filtration rate (GFR) decline or CKD. We studied nephropathy progression in 303 SCA participants in a prospective, multicenter, longitudinal study. We collected steady-state urine and serum samples yearly and assessed albumin/creatinine ratio (ACR), estimated GFR (eGFR), and SCA and nephropathy biomarkers. Participants with albuminuria (ACR ≥30 mg/g) for ≥2 annual measurements were classified as having persistent albuminuria (PA). At baseline (mean age, 21 years; range, 2-64 years), 32% had albuminuria. In longitudinal multivariate analysis, ACR was associated with sex, anemia, older age, and higher bilirubin and kidney injury molecule-1 levels. Albuminuria increased with age by 3.5 mg/g per year (P < .0001). Of 175 participants with ≥3 annual samples, 81% with baseline albuminuria ≥100 mg/g developed PA. Decreased eGFR and adult CKD were associated with PA (P = .002 and P = .02, respectively), but not with baseline albuminuria. Rate of eGFR decline was steeper among adults (but not children) with albuminuria, compared with those without (P = .02). Participants with PA were more likely to have rapid eGFR decline compared with those without (P = .03). In this longitudinal study, albuminuria progressed with age, and adults with albuminuria had worse eGFR decline than those without. Albuminuria ≥100 mg/g predicted PA, which was associated with rapid eGFR decline and CKD development in adults with SCA. This trial was registered at www.clinicaltrials.gov as #NCT02239016.

摘要

镰状细胞肾病导致慢性肾脏病(CKD),这与镰状细胞贫血症(SCA)患者的高发病率和死亡率密切相关。蛋白尿是镰状肾病的早期表现;然而,对于蛋白尿的进展或其与肾小球滤过率(GFR)下降或 CKD 的相关性知之甚少。我们对 303 名镰状细胞贫血症患者进行了一项前瞻性、多中心、纵向研究,以研究肾病的进展情况。我们每年收集稳定的尿液和血清样本,并评估白蛋白/肌酐比值(ACR)、估计肾小球滤过率(eGFR)以及镰状细胞贫血症和肾病生物标志物。如果患者的蛋白尿(ACR≥30mg/g)连续两年以上,则被归类为持续性蛋白尿(PA)。在基线时(平均年龄为 21 岁,范围为 2-64 岁),32%的患者存在蛋白尿。在纵向多变量分析中,ACR 与性别、贫血、年龄较大以及胆红素和肾损伤分子-1 水平较高有关。白蛋白尿每年增加 3.5mg/g(P<0.0001)。在 175 名具有≥3 个年度样本的患者中,基线白蛋白尿≥100mg/g 的患者中 81%发展为 PA。eGFR 下降和成人 CKD 与 PA 相关(P=0.002 和 P=0.02),但与基线白蛋白尿无关。与无蛋白尿的患者相比,有蛋白尿的成年人的 eGFR 下降速度更快(P=0.02)。在这项纵向研究中,白蛋白尿随年龄进展,有蛋白尿的成年人的 eGFR 下降速度比无蛋白尿的成年人更快。有蛋白尿的患者与无蛋白尿的患者相比,eGFR 下降速度更快(P=0.03)。在这项纵向研究中,白蛋白尿随年龄进展,有蛋白尿的成年人的 eGFR 下降速度比无蛋白尿的成年人更快。有蛋白尿的患者与无蛋白尿的患者相比,eGFR 下降速度更快(P=0.03)。在这项纵向研究中,白蛋白尿随年龄进展,有蛋白尿的成年人的 eGFR 下降速度比无蛋白尿的成年人更快。该试验在 www.clinicaltrials.gov 上注册为 #NCT02239016。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93ba/7160281/91e81a16583a/advancesADV2019001378absf1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验